494769-32-3

Upstream product

• 2941-78-8 2-Amino-5-methylbenzoic acid 

Relevant academic research and scientific papers

Synthesis and antiproliferative evaluation of novel steroid-benzisoselenazolone hybrids

The two different types of steroidal benzisoselenazolone hybrids were synthesized by incorporating benzisoselenazolone scaffold into dehydroepiandrosterone and B-norcholesterol. The antiproliferative activity of the synthesized compounds against some carcinoma cell lines were investigated. The results showed that some of these compounds have better inhibitory activity than abiraterone on the proliferation of tumor cells associated with human growth hormone, and have less cytotoxicity on normal human cells. In particular, the IC50 values of the compound 8a and 8f are 5.4 and 6.5 μmol/L against human ovarian carcinoma (SKOV3) cell line, and possess SI values of 13.9 and 10.5, respectively. The information obtained from the studies may be useful for the design of novel chemotherapeutic drugs.

Synthesis and applications of benzisoselenazolone modified nitrosourea compound

The present invention relates to a benzisoselenazolone modified nitrosourea compound and applications thereof, wherein the benzisoselenazolone modified nitrosourea compound is represented by a general formula I, has excellent antitumor activity, and can be widely used for preparing antitumor drugs. The general formula I is defined in the specification.

Benzisoselenazolone compound metabolite and synthesis method and application thereof

The invention provides a benzisoselenazolone derivative and pharmacologically acceptable salt thereof (please see the formula I in the specification). R1 and R2 are identical or different, and independently are hydrogen, halogen (such as F and Cl), cyano, nitryl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthiol, N(C1-C6 alkyl)2, NH(C1-C6 alkyl), COOH and SO3H. The invention further provides a medicinal composition containing the compound and application of the composition in preparation of antineoplastic drugs.

Inhibition of thioredoxin reductase by a novel series of bis-1,2-benzisoselenazol-3(2H)-ones: Organoselenium compounds for cancer therapy

Thioredoxin reductase (TrxR) is critical for cellular redox regulation and is involved in tumor proliferation, apoptosis and metastasis. Its C-terminal redox-active center contains a cysteine (Cys497) and a unique selenocysteine (Sec498), which are exposed to solvent and easily accessible. Thus, it is becoming an important target for anticancer drugs. Selective inhibition of TrxR by 1,2-(bis-1,2-benzisoselenazol-3(2H)-one)ethane (4a) prevents proliferation of several cancer cell lines both in vivo and in vitro. Using the structure of 4a as a starting point, a series of novel bis-1,2-benzisoselenazol-3(2H)-ones was designed, prepared and tested to explore the structure-activity relationships (SARs) for this class of inhibitor and to improve their potency. Notably, 1,2-(5,5′-dimethoxybis(1,2-benzisoselenazol-3(2H)-one))ethane (12) was found to be more potent than 4a in both in vitro and in vivo evaluation. Its binding sites were confirmed by biotin-conjugated iodoacetamide assay and a SAR model was generated to guide further structural modification.